NGM Документы SEC - NGM Biopharmaceuticals, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	5493008V5DSDZIGQOP17
CIK	1426332

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NGM Biopharmaceuticals, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

April 15, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specifie
April 5, 2024	POS AM	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	S-8 POS	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	S-8 POS	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	S-8 POS	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	EX-3.2	BYLAWS NGM BIOPHARMACEUTICALS, INC. (A Delaware Corporation) Exhibit 3.2 Final Form BYLAWS of NGM BIOPHARMACEUTICALS, INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II STOCKHOLDERS 2 ARTICLE III DIRECTORS 6 ARTICLE IV COMMITTEES OF THE BOARD 8 ARTICLE V OFFICERS 8 ARTICLE VI INDEMNIFICATION 10 ARTICLE VII GENERAL PROVISIONS 11 i ARTICLE I DEFINITIONS As used in these Bylaws, unless the context otherwise requires, the te
April 5, 2024	8-K	Changes in Control of Registrant, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
April 5, 2024	SC 13E3/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) NGM BIOPHARMACEUTICALS, INC. (Name of the Issue UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) NGM BIOPHARMACEUTICALS, INC. (Name of the Issuer) NGM Biopharmaceuticals, Inc. David J. Woodhouse, Ph.D. William J. Rieflin (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per s
April 5, 2024	S-8 POS	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) NGM BIOPHARMACEUTICALS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company) NGM BIOPHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Se
April 5, 2024	SC 13D/A	NGM / NGM Biopharmaceuticals, Inc. / COLUMN GROUP L P - AMENDMENT NO. 8 Activist Investment SC 13D/A 1 eh24046588313da8-ngm.htm AMENDMENT NO. 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) James Evangelista The Column Group, LP 1 Letterman Drive, Building D
April 5, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) ATLAS NEON MERGER SUB, INC. (Name of Filing Persons (Offeror)) ATLAS NEON PARENT, INC. (Name of Filing Persons (Parent of Offeror)) THE C
April 5, 2024	EX-99.1	NGM Bio Announces Closing of Tender Offer EX-99.1 Exhibit 99.1 NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) – NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned
April 5, 2024	EX-3.1	SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NGM BIOPHARMACEUTICALS, INC. Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NGM BIOPHARMACEUTICALS, INC. 1. The name of the Corporation is: NGM Biopharmaceuticals, Inc. 2. The address of the Corporation’s registered office in the State of Delaware is 850 New Burton Road, Suite 201, City of Dover, County of Kent, 19904. The name of its registered agent at such address is Cogency Global Inc. 3. The nat
April 5, 2024	S-8 POS	As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No.
April 5, 2024	EX-99.(A)(1)(J)	NGM Bio Announces Closing of Tender Offer Exhibit (a)(1)(J) NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) – NGM Biopharmaceuticals, Inc.
April 4, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
March 29, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) NGM BIOPHARMACEUTICALS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company) NGM BIOPHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Se
March 22, 2024	SC TO-T/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) ATLAS NEON MERGER SUB, INC. (Name of Filing Persons (Offeror)) ATLAS NEON PARENT, INC. (Name of Filing Persons (Parent of Offeror)) THE C
March 22, 2024	SC 13E3/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) NGM BIOPHARMACEUTICALS, INC. (Name of the Issue UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) NGM BIOPHARMACEUTICALS, INC. (Name of the Issuer) NGM BIOPHARMACEUTICALS, INC. DAVID J. WOODHOUSE, PH.D. WILLIAM J. RIEFLIN (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per s
March 22, 2024	CORRESP	**** Richard Aftanas Partner Hogan Lovells US LLP 390 Madison Avenue New York, NY 10017 T +1 212 918 3267 F +1 212 918 3100 raftanas@hoganlovells.
March 22, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) NGM BIOPHARMACEUTICALS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company) NGM BIOPHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Se
March 11, 2024	EX-99.1	NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results •Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second qu
March 11, 2024	EX-10.16	Offer Letter and Arbitration Agreement, by and between the Registrant and Jean-Frédéric Viret, Ph.D., dated as of October 20, 2023 Exhibit 10.16 October 18, 2023 Jean-Frédéric Viret Dear Jean: On behalf of NGM Biopharmaceuticals, Inc. (“NGM Bio” or the “Company”), we are pleased to offer you employment with the Company as Chief Financial Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to you joining our exceptional team on November 3, 2023. Below are details of th
March 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 NGM Biopharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
March 11, 2024	EX-21.1	Subsidiaries of NGM Biopharmaceuticals, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Incorporation or Organization NGM Biopharmaceuticals Australia Pty Ltd. Australia
March 11, 2024	EX-97.1	NGM Biopharmaceuticals, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 INCENTIVE COMPENSATION RECOUPMENT POLICY The Board of Directors (the “Board”) of NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation (as
March 11, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
March 11, 2024	EX-10.14	Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019. Exhibit 10.14 January 16, 2019 Hsiao D. Lieu, M.D. Dear Hsiao, On behalf of NGM Biopharmaceuticals, Inc. (“NGM” or the “Company”), we are pleased that you will be joining the Company as Senior Vice President, Chief Medical Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. Below are details of the com
March 11, 2024	EX-10.15	Offer Letter Agreement, by and between the Registrant and Valerie L. Pierce, dated as of August 6, 2019, and related information. Exhibit 10.15 August 6, 2019 Valerie L. Pierce, Esq. Dear Valerie, On behalf of NGM Biopharmaceuticals, Inc. ("NGM" or the "Company"), we are pleased that you will be joining the Company as Senior Vice President, General Counsel and Chief Compliance Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. B
March 8, 2024	EX-99.(A)(1)(A)	Offer to Purchase All Outstanding Shares of Common Stock NGM BIOPHARMACEUTICALS, INC. An Offer Price of $1.55 per Share in Cash ATLAS NEON MERGER SUB, INC., a wholly owned subsidiary of ATLAS NEON PARENT, INC., an affiliate of THE COLUMN GROUP, LP, T TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of NGM BIOPHARMACEUTICALS, INC.
March 8, 2024	EX-99.(E)(5)	ROLLOVER AGREEMENT EXHIBIT (e)(5) ROLLOVER AGREEMENT This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc.
March 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) NGM BIOPHARMACEUTICS, INC. DAVID J. WOODHOUSE, PH.D. WILLIAM J. RIEFLIN (Exact Name of Registrant and Name of Person Filing Statement) Table 1 – Transaction Value Transaction Valuation Fee r Exhibit 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) NGM BIOPHARMACEUTICS, INC.
March 8, 2024	EX-99.(C)(3)	GUGGENHEIM Guggenheim Securities Project Atlas PRELIMINARY DRAFT Subject to Revisions Preliminary Financial Analysis January 19, 2024 Privileged and Confidential Exhibit (c)(3) GUGGENHEIM Guggenheim Securities Project Atlas PRELIMINARY DRAFT Subject to Revisions Preliminary Financial Analysis January 19, 2024 Privileged and Confidential DRAFT – SUBJECT TO REVISIONS Certain Disclosures and Other Considerations In connection with the engagement of Guggenheim Securities, LLC (“Guggenheim Securities,” “we” or “us”) by the client referred to herein (the “Company”), we have prepared this presentation (together with any related oral commentary and any supplemental materials or updates, this “Presentation”) solely to assist the Company’s senior management and Special Committee of the Board of Directors (the “Special Committee”) in considering the proposed transaction described herein (the “Transaction”).
March 8, 2024	EX-99.(E)(6)	JOINDER AGREEMENT Dated: March 6, 2024 EXHIBIT (e)(6) JOINDER AGREEMENT Dated: March 6, 2024 This Joinder Agreement (“Joinder Agreement”) is executed by the undersigned (“Additional Holders”), pursuant to the terms of the Rollover Agreement, dated as of February 25, 2024, a copy of which is attached hereto and is incorporated herein by reference (the “Rollover Agreement”).
March 8, 2024	EX-99.(A)(1)(E)	Notice of Offer to Purchase All Outstanding Shares of Common Stock of NGM BIOPHARMACEUTICALS, INC. at An Offer Price of $1.55 per Share in Cash Pursuant to the Offer to Purchase Dated March 8, 2024 by ATLAS NEON MERGER SUB, INC., a wholly owned subsi Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
March 8, 2024	EX-99.(A)(1)(D)	Offer to Purchase All Outstanding Shares of Common Stock NGM BIOPHARMACEUTICALS, INC. An Offer Price of $1.55 per Share in Cash ATLAS NEON MERGER SUB, INC., a wholly owned subsidiary of ATLAS NEON PARENT, INC., an affiliate of THE COLUMN GROUP, LP, T Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of NGM BIOPHARMACEUTICALS, INC.
March 8, 2024	EX-99.(A)(1)(B)	Letter of Transmittal To Tender Shares of Common Stock NGM BIOPHARMACEUTICALS, INC. a Delaware corporation AN OFFER PRICE OF $1.55 PER SHARE IN CASH Pursuant to the Offer to Purchase Dated March 8, 2024 ATLAS NEON MERGER SUB, INC., a wholly owned sub Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of NGM BIOPHARMACEUTICALS, INC.
March 8, 2024	EX-99.(C)	February 25, 2024 Exhibit (c) Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 GuggenheimPartners.
March 8, 2024	EX-99.(F)	2 Exhibit (f) Section 262 of the General Corporation Law of the State of Delaware § 262 Appraisal rights (a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d) of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who
March 8, 2024	SC 13E3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 NGM BIOPHARMACEUTICALS, INC. (Name of the Issuer) NGM BIOPHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT PURSUANT TO SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 NGM BIOPHARMACEUTICALS, INC. (Name of the Issuer) NGM BIOPHARMACEUTICALS, INC. DAVID J. WOODHOUSE, PH.D. WILLIAM J. RIEFLIN (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Cla
March 8, 2024	EX-99.(C)(4)	GUGGENHEIM GUGGENHEIM Securities Project Atlas Presentation to the Special Committee of the Board of Directors February 25, 2024 Privileged and Confidential Exhibit (c)(4) GUGGENHEIM GUGGENHEIM Securities Project Atlas Presentation to the Special Committee of the Board of Directors February 25, 2024 Privileged and Confidential Certain Disclosures and Other Considerations In connection with the engagement of Guggenheim Securities, LLC (“Guggenheim Securities,” “we” or “us”) by the client referred to herein (the “Company”), we have prepared this present
March 8, 2024	EX-99.(D)(2)	NON-DISCLOSURE AGREEMENT Exhibit (d)(2) NON-DISCLOSURE AGREEMENT This Non-Disclosure Agreement (“Agreement”), effective as of October 31, 2023 (“Effective Date”), is entered into by and between NGM Biopharmaceuticals, Inc.
March 8, 2024	EX-99.(E)(4)	ROLLOVER AGREEMENT EXHIBIT (e)(4) ROLLOVER AGREEMENT This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc.
March 8, 2024	EX-99.(D)(5)	JOINDER AGREEMENT Dated: March 6, 2024 Exhibit (d)(5) JOINDER AGREEMENT Dated: March 6, 2024 This Joinder Agreement (“Joinder Agreement”) is executed by the undersigned (“Additional Holders”), pursuant to the terms of the Rollover Agreement, dated as of February 25, 2024, a copy of which is attached hereto and is incorporated herein by reference (the “Rollover Agreement”).
March 8, 2024	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) ATLAS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) ATLAS NEON MERGER SUB, INC. (Name of Filing Persons (Offeror)) ATLAS NEON PARENT, INC. (Name of Filing Persons (Parent of Offeror)) THE COLUMN GROUP, LP (N
March 8, 2024	EX-99.(D)(2)	NON-DISCLOSURE AGREEMENT Exhibit (d)(2) NON-DISCLOSURE AGREEMENT This Non-Disclosure Agreement (“Agreement”), effective as of October 31, 2023 (“Effective Date”), is entered into by and between NGM Biopharmaceuticals, Inc.
March 8, 2024	EX-99.(C)(2)	GUGGENHEIM Guggenheim Securities Project Atlas DRAFT Subject to Revisions Situation Overview January 19, 2024 Privileged and Confidential Exhibit (c)(2) GUGGENHEIM Guggenheim Securities Project Atlas DRAFT Subject to Revisions Situation Overview January 19, 2024 Privileged and Confidential DRAFT – SUBJECT TO REVISIONS Certain Disclosures and Other Considerations In connection with the engagement of Guggenheim Securities, LLC (“Guggenheim Securities,” “we” or “us”) by the client referred to herein (the “Company”), we have prepared this presentation (together with any related oral commentary and any supplemental materials or updates, this “Presentation”) solely to assist the Company’s senior management and Special Committee of the Board of Directors (the “Special Committee”) in considering the proposed transaction described herein (the “Transaction”).
March 8, 2024	SC 14D9	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) NGM BIOPHARMACEUTICALS, INC. (N Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company) NGM BIOPHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Tit
March 8, 2024	EX-99.(A)(1)(C)	Offer to Purchase All Outstanding Shares of Common Stock NGM BIOPHARMACEUTICALS, INC. An Offer Price of $1.55 per Share in Cash ATLAS NEON MERGER SUB, INC., a wholly owned subsidiary of ATLAS NEON PARENT, INC., an affiliate of THE COLUMN GROUP, LP, T Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of NGM BIOPHARMACEUTICALS, INC.
March 8, 2024	EX-99.(E)(12)	Severance Benefit Addendum EXHIBIT(e)(12) Severance Benefit Addendum This Severance Benefit Addendum (“Addendum”), effective as of [*], to the employment offer letter (“Offer Letter”) dated [] by and between [**] (“Executive”) and NGM Biopharmaceuticals, Inc.
March 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Schedule TO (Form Type) NGM BIOPHARMACEUTICS, INC. (Name of Subject Company (Issuer)) ATLAS NEON MERGER SUB, INC. (Name of Filing Person — Offeror) a wholly-owned subsidiary of ATLAS NEON PARENT, INC. (Name of Filing Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) NGM BIOPHARMACEUTICS, INC.
February 26, 2024	EX-99.1	Press Release of the Company issued on February 26, 2024. EXHIBIT 99.1 NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP · NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction.
February 26, 2024	EX-99.3	TCG Rollover Agreement, between certain of the Reporting Persons, Parent and Merger Sub, dated February 25, 2024. EX-99.3 2 eh240451717ex03.htm EXHIBIT 3 EXHIBIT 3 ROLLOVER AGREEMENT This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), (ii) Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and (iii) the Persons listed on the signature pages hereto under
February 26, 2024	SC 13D/A	NGM / NGM Biopharmaceuticals, Inc. / COLUMN GROUP L P - AMENDMENT NO. 7 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) James Evangelista The Column Group, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415) 865-205
February 26, 2024	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) NGM BIOPHARMACEUTICALS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company) NGM BIOPHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Se
February 26, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2024 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
February 26, 2024	EX-99.4	Stockholder Rollover Agreement, between certain stockholders, Parent and Merger Sub, dated February 25, 2024 EX-99.4 3 eh240451717ex04.htm EXHIBIT 4 EXHIBIT 4 ROLLOVER AGREEMENT This ROLLOVER AGREEMENT (this “Agreement”) is dated as of February 25, 2024, by and among (i) Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), (ii) Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), (iii) the Persons listed on the signature pages hereto under the
February 26, 2024	EX-2.1	Agreement and Plan of Merger, dated February 25, 2024, by and among NGM Biopharmaceuticals, Inc., Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF FEBRUARY 25, 2024 AMONG ATLAS NEON PARENT, INC., ATLAS NEON MERGER SUB, INC. AND NGM BIOPHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 SECTION 1.02 Interpretation and Rules of Construction 11 ARTICLE II THE OFFER 12 SECTION 2.01 The Offer 12 SECTION 2.02 Company Actions 14 ARTICLE III THE MERGER 1
February 26, 2024	EX-99.1	NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP Exhibit 99.1 NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP • NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction
February 26, 2024	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 NGM BIOPHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) ATLAS NEON MERGER SUB, INC. (Name of Filing Persons (Offeror)) ATLAS NEON PARENT, INC. (Name of Filing Persons (Parent of Offeror)) THE COLUMN GROUP, LP (N
February 26, 2024	EX-99.1	NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP Exhibit 99.1 NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP • NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction
February 26, 2024	EX-10.1	Limited Guaranty, dated February 25, 2024 Exhibit 10.1 Execution Version LIMITED GUARANTY This Limited Guaranty, dated as of February 25, 2024 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by each of the parties listed on Exhibit A hereto (each, a “Guarantor” and collectively, the “Guarantors”), is made in favor of NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Guaranteed Party”).
February 14, 2024	SC 13G/A	NGM / NGM Biopharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 62921N105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 13, 2024	SC 13G/A	NGM / NGM Biopharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01552-ngmbiopharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: NGM Biopharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 62921N105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box
January 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 NGM Biopharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 NGM Biopharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
December 29, 2023	SC 13D/A	NGM / NGM Biopharmaceuticals, Inc. / COLUMN GROUP L P - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) James Evangelista The Column Group, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415) 865-205
December 29, 2023	EX-99.1	Letter, dated December 28, 2023, from certain Reporting Persons to the Board EX-99.1 2 eh230432395ex01.htm EXHIBIT 1 EXHIBIT 1 The Column Group, LP The Column Group GP, LP The Column Group Management, LP The Column Group II, LP The Column Group III, LP The Column Group III-A, LP The Column Group IV, LP The Column Group IV-A, LP The Column Group Opportunity III, LP Ponoi Capital, LP Ponoi Capital II, LP 1 Letterman Drive Building D, Suite DM-900 San Francisco, CA 94129 Dece
December 29, 2023	EX-99.2	Joint Filing Agreement EX-99.2 3 eh230432395ex02.htm EXHIBIT 2 EXHIBIT 2 EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Amendment No. 6 to Schedule 13D is filed on behalf of each of us. Dated: December 29, 2023 THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ James Evangelista, Partner & Chief Financial Officer By: /s/ James Evangelist
December 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 NGM BIOPHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 NGM BIOPHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
November 2, 2023	EX-10.1	Offer Letter and Arbitration Agreement, by and between the Registrant and Jean-Frédéric Viret, Ph.D., dated as of October 20, 2023 Exhibit 10.1 October 18, 2023 Jean-Frédéric Viret Dear Jean: On behalf of NGM Biopharmaceuticals, Inc. (“NGM Bio” or the “Company”), we are pleased to offer you employment with the Company as Chief Financial Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to you joining our exceptional team on November 3, 2023. Below are details of the
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
November 2, 2023	EX-10.2	Amendment No. 10 on October 31, 2023 to the Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014. CONFIDENTIAL Exhibit 10.2 [*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed. AMENDMENT No. 10 To the MULTI-PRODUCT LICENCE AGREEMENT dated 31 October 2014 between LONZA SALES AG and NGM BIOPHARMACEUTICALS, INC. CONFIDENTIAL This Amendment No. 10 (“Amen
November 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 NGM Biopharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
November 2, 2023	EX-99.1	NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights Exhibit 99.1 NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights •Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023 •Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438 •Selected for an oral plenary presentation of data from Phase 2b ALPINE 4 trial of aldafermin in compensated
October 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 NGM Biopharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
September 11, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of In
August 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 NGM Biopharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
August 4, 2023	S-3/A	As filed with the Securities and Exchange Commission on August 4, 2023 S-3/A As filed with the Securities and Exchange Commission on August 4, 2023 Registration No.
August 4, 2023	424B5	$100,000,000 NGM Biopharmaceuticals, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272509 Prospectus $100,000,000 NGM Biopharmaceuticals, Inc. Common Stock We have entered into Amendment No. 1 to the Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus. The controlling provisions of the amen
August 3, 2023	EX-99.1	NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights Exhibit 99.1 NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights •Announced positive data from Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and bile acid malabsorption (BAM) •Announced topline positive data from Phase 2b ALPINE 4 trial of aldafermin; study met its prima
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 NGM Biopharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
August 1, 2023	CORRESP	NGM BIOPHARMACEUTICALS, INC. 333 Oyster Point Boulevard South San Francisco, California 94080 (650) 243-5555 NGM BIOPHARMACEUTICALS, INC. 333 Oyster Point Boulevard South San Francisco, California 94080 (650) 243-5555 August 1, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: NGM Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 8, 2023 File No. 333-272509 Ladies and Gentlemen:
June 8, 2023	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associa
June 8, 2023	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associa
June 8, 2023	EX-4.3	Form of Debt Indenture. EX-4.3 Exhibit 4.3 NGM BIOPHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE DATED AS OF [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 2.01 Designation and Terms of Securities 4 2.02 Form of Securities and Trustee’s Certificate 6 2.03 Denominati
June 8, 2023	S-3	As filed with the Securities and Exchange Commission on June 8, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 Exhibit 4.5 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] org
June 8, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NGM Biopharmaceuticals, Inc.
June 8, 2023	EX-1.1	Amendment No. 1 to Open Market Sale AgreementSM, dated June 7, 2023, between the Company and Jefferies. Exhibit 1.1 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM June 7, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), who are pa
June 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 NGM Biopharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 NGM Biopharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 NGM Biopharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissio
May 4, 2023	EX-99.1	NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data Exhibit 99.1 NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data •Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engi
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
May 4, 2023	EX-10.1	Non-Employee Director Compensation Policy Exhibit 10.1 NGM Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy Approved by the Board of Directors: March 8, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of NGM Biopharmaceuticals, Inc. (“NGM”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Dire
April 7, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NGM Biopharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
April 4, 2023	EX-99.1	April 4, 2023 Exhibit 99.1 April 4, 2023 Subject Line: Important Business Updates Dear Explorers: This morning I am announcing a difficult, but necessary, decision. NGM is undergoing a restructuring, which includes reducing the size of our NGM team by 75 of our friends and colleagues, or approximately one-third of our existing footprint. All functions are impacted by this restructuring – G&A, research and devel
March 29, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 29, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
February 28, 2023	EX-10.9	Amended and Restated Non-Employee Director Executive Compensation Policy Exhibit 10.9 Amended Non-Employee Director Compensation Policy NGM BIOPHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Approved by the Board of Directors: June 29, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of NGM Biopharmaceuticals, Inc. (“NGM”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive th
February 28, 2023	S-8	As filed with the U.S. Securities and Exchange Commission on February 28, 2023 As filed with the U.S. Securities and Exchange Commission on February 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of Incorporation or organizat
February 28, 2023	EX-FILING FEES	Filing fee table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 NGM Biopharmaceuticals, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share – Amended and Restated 2018 Equity Incentive Plan Rule 457(c) and 457(h) 3,275,416
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
February 28, 2023	EX-21.1	Subsidiaries of NGM Biopharmaceuticals, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Incorporation or Organization NGM Biopharmaceuticals Australia Pty Ltd. Australia
February 28, 2023	EX-10.14	Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019. Exhibit 10.14 January 16, 2019 Hsiao D. Lieu, M.D. Dear Hsiao, On behalf of NGM Biopharmaceuticals, Inc. (“NGM” or the “Company”), we are pleased that you will be joining the Company as Senior Vice President, Chief Medical Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. Below are details of the com
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 NGM Biopharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
February 28, 2023	EX-99.1	NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results •Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress •Initiated a Phase 1b cohort of the ongoing Phase 1/1b trial evaluating NG
February 13, 2023	SC 13G/A	NGM / NGM Biopharmaceuticals Inc / Rho Ventures V, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2023	SC 13G	NGM / NGM Biopharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: NGM Biopharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 62921N105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(
December 20, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): NOVEMBER 3, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
November 3, 2022	EX-99.1	NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results ?Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham ?Presented updat
October 28, 2022	SC 13G	NGM / NGM Biopharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 62921N105 (CUSIP Number) October 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
October 17, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 NGM Biopharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
October 17, 2022	EX-99.1	NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration EX-99.1 Exhibit 99.1 NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration • Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham • NGM621 showed favorable safety and tolerability, with no
August 4, 2022	EX-10.1	Lease agreement, by and between NGM Biopharmaceuticals, Inc. and HCP BTC, LLC, dated as of July 7, 2022. Exhibit 10.1 BRITANNIA OYSTER POINT LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and NGM BIOPHARMACEUTICALS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
August 4, 2022	EX-99.1	NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results ?Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA? (pembrolizumab) for the treatment of patients with advanced solid tumors ?Initiated the Phase1b portion of the Phase 1/2 trial of NGM707, a dual ILT2/ILT4
July 13, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
June 30, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
June 10, 2022	SC 13D/A	NGM / NGM Biopharmaceuticals Inc / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) James Evangelista The Column Group, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415
May 24, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 20, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
May 5, 2022	EX-10.1	Letter Agreement, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of March 30, 2022. Confidential Exhibit 10.1 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL March 30, 2022 Merck Sharp & Dohme Corp. [*] Attention: Office of Secretary Merck Sharp & Dohme Corp. [*] Attention: VP, Transactions, Business Development & Licensing, MRL Re: NGM621
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissio
May 5, 2022	EX-99.1	NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results ?Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA? (pembrolizumab), for the treatment of patients with advanced solid tumors ?Presented preclinical research for NGM707, a dual ILT2/ILT4 antagonist antibody
April 28, 2022	8-K/A	Temporary Suspension of Trading Under Registrant's Employee Benefit Plans UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of In
April 6, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 6, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 ngm2022def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
March 10, 2022	EX-99.1	NOTICE OF BLACKOUT PERIOD DATE: March 10, 2022 TO: Directors and Executive Officers of NGM Biopharmaceuticals, Inc. FROM: Valerie Pierce, Secretary, Senior Vice President, General Counsel and Chief Compliance Officer RE: Notice Regarding Matching Pla Exhibit 99.1 NOTICE OF BLACKOUT PERIOD DATE: March 10, 2022 TO: Directors and Executive Officers of NGM Biopharmaceuticals, Inc. FROM: Valerie Pierce, Secretary, Senior Vice President, General Counsel and Chief Compliance Officer RE: Notice Regarding Matching Plan and 401(k) Plan Blackout Period and Trading Restrictions On March 10, 2022, NGM Biopharmaceuticals, Inc. (the ?Company?) received notic
March 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
March 1, 2022	S-8	As filed with the U.S. Securities and Exchange Commission on March 1, 2022 As filed with the U.S. Securities and Exchange Commission on March 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of Incorporation or organization)
March 1, 2022	EX-FILING FEES	Filing fee table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 NGM Biopharmaceuticals, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share ? Amended and Restated 2018 Equity Incentive Plan Rule 457(c) and 457(h) 3,118,508
March 1, 2022	EX-10.23	Amendment No. 9 on November 3, 2021 to Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 CONFIDENTIAL Exhibit 10.23 [*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed AMENDMENT No. 9 To the MULTI-PRODUCT LICENCE AGREEMENT dated 31 October 2014 between LONZA SALES AG and NGM BIOPHARMACEUTICALS, INC. CONFIDENTIAL This Amendment No. 9 (?Amendm
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
March 1, 2022	EX-21.1	Subsidiaries of NGM Biopharmaceuticals, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Incorporation or Organization NGM Biopharmaceuticals Australia Pty Ltd. Australia
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
March 1, 2022	EX-99.1	NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results ?Advanced programs across NGM Bio?s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: ?Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an anti-complement C3 antibody prod
February 3, 2022	EX-99.A	Joint Filing Statement EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Amendment No.
February 3, 2022	SC 13D/A	NGM / NGM Biopharmaceuticals Inc / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) James Evangelista The Column Group, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415
November 4, 2021	EX-99.1	NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results ?Presented preliminary Phase 1a/1b trial findings at ESMO 2021 for NGM120, a GFRAL antagonist antibody product candidate, that showed the drug was well tolerated in advanced solid tumors and provided encouraging initial signals of anti-cancer activity in patients with metastatic pancreatic cancer ?In
November 4, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No.
November 4, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No.
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
November 4, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIO
August 5, 2021	EX-99.1	NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results ?Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022 ?Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanc
August 5, 2021	EX-10.2	Forms of Stock Option Agreement and Notice of Grant of Stock Option for Non-employee Directors Under the Amended and Restated 2018 Equity Incentive Plan Exhibit 10.2 NGM BIOPHARMACEUTICALS, INC. 2018 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE NGM Biopharmaceuticals, Inc. (the ?Company?) has awarded to Participant an option to purchase up to the number of shares of Common Stock set forth below (the ?Option?) under its 2018 Equity Incentive Plan (the ?Plan?). Participant: Date of Grant: Number of Shares Subject to Option: Type of Grant: Nonstat
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
August 5, 2021	EX-10.1	Amended and Restated Research Collaboration, Product Development and License Agreement, made effective as of June 30, 2021, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp. CONFIDENTIAL TREATMENT Exhibit 10.1 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL AMENDED AND RESTATED RESEARCH COLLABORATION, PRODUCT DEVELOPMENT AND LICENSE AGREEMENT by and between NGM BIOPHARMACEUTICALS, INC. and MERCK SHARP & DOHME CORP. AMENDED AND REST
July 1, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
June 10, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 24, 2021	EX-99.1	NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH Exhibit 99.1 NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH ? Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placebo ? Statistical significance achieved versus placebo on certain secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, includi
May 24, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 6, 2021	EX-99.1	NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results ?Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarter ?Continued enrollment in Phase 2 CATALINA study of NGM621 in patients with geographic atrophy and expect to complete enrollment by mid-year ?A
May 6, 2021	EX-10.3	Offer Letter Agreement, by and between the Registrant and Valerie L. Pierce, dated as of August 6, 2019, and related information. Exhibit 10.3 August 6, 2019 Valerie L. Pierce, Esq. Dear Valerie, On behalf of NGM Biopharmaceuticals, Inc. ("NGM" or the "Company"), we are pleased that you will be joining the Company as Senior Vice President, General Counsel and Chief Compliance Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. Be
May 6, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
May 6, 2021	EX-10.2	Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019. Exhibit 10.2 January 16, 2019 Hsiao D. Lieu, M.D. Dear Hsiao, On behalf of NGM Biopharmaceuticals, Inc. (?NGM? or the ?Company?), we are pleased that you will be joining the Company as Senior Vice President, Chief Medical Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. Below are details of the comp
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissio
April 28, 2021	EX-99.1	Press release, dated April 28, 2021, titled “NGM Announces Nomination of Roger M. Perlmutter for Election to its Board of Directors.” Exhibit 99.1 NGM Announces Nomination of Roger M. Perlmutter for Election to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) ? NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the nomination of Roger M. Perlmutter, M.D., Ph.D., to stand for el
April 28, 2021	EX-99.1	NGM Announces Nomination of Roger M. Perlmutter for Election to its Board of Directors Exhibit 99.1 NGM Announces Nomination of Roger M. Perlmutter for Election to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) ? NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the nomination of Roger M. Perlmutter, M.D., Ph.D., to stand for el
April 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
April 28, 2021	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
April 28, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 28, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 15, 2021	S-8	- S-8 As filed with the U.S. Securities and Exchange Commission on March 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of Incorporation or organization
March 15, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIOPHARMACEUTICALS, I
March 15, 2021	EX-10.18	Amendment No. 8 on February 10, 2021 to Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 CONFIDENTIAL [*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.
March 15, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
March 15, 2021	EX-10.1	Letter Agreement, dated as of March 12, 2021, by and between Merck Sharp & Dohme Corp. and NGM Biopharmaceuticals, Inc. Exhibit 10.1 126 E Lincoln Ave. Rahway, NJ 07065 U.S.A. merck.com March 12, 2021 NGM Biopharmaceuticals, Inc. 333 Oyster Point Blvd. South San Francisco, CA 94080 Attention: Chief Executive Officer Facsimile: 650-583-1646 Cooley LLP 3175 Hanover St. Palo Alto, CA 94304 Attention: Marya Postner Facsimile: 650-583-1646 Re: Research Collaboration, Product Development and License Agreement, dated as o
March 15, 2021	EX-21.1	Subsidiaries of NGM Biopharmaceuticals, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Incorporation or Organization NGM Biopharmaceuticals Australia Pty Ltd. Australia
March 15, 2021	EX-10.17	Amendment No. 7 on December 22, 2020 to Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 CONFIDENTIAL [*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.
March 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
March 4, 2021	EX-99.1	NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results ? Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fourth quarter 2020: o Presented first-in-human results from Phase 1 clinical trial of NGM621 in patients with geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2020
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 6 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 6 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 6, 2021	424B5	4,629,630 Shares NGM Biopharmaceuticals, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
January 6, 2021	EX-99.1	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 Unless the context otherwise requires, the terms “NGM Biopharmaceuticals”, “NGM”, “we”, “us” and “our” in this Exhibit 99.1 refer to NGM Biopharmaceuticals, Inc. and its wholly-owned subsidiary, taken as a whole. This Exhibit 99.1 includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Ex
January 6, 2021	EX-1.1	Underwriting Agreement, dated as of January 5, 2021, by and among NGM Biopharmaceuticals, Inc., Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC. EX-1.1 Exhibit 1.1 NGM Biopharmaceuticals, Inc. Common Stock, par value $0.001 per share Underwriting Agreement January 5, 2021 Goldman Sachs & Co. LLC Citigroup Global Markets Inc. Cowen and Company, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Citigroup Global Market
January 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporatio
January 4, 2021	424B5	Subject to completion, dated January 4, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
November 20, 2020	SC 13G/A	NGM / NGM BIOPHARMACEUTICALS INC / Topspin Fund L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) November 20, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
November 12, 2020	EX-99.1	NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results • NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline: o Initiated a Phase 2 clinical trial of NGM621, an anti-complement C3 antibody, in patients with geographic atrophy (GA) o Announced expansion of oncology portfol
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
August 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commi
August 12, 2020	EX-10.1	Offer Letter Agreement, by and between the Registrant and Siobhan Nolan Mangini, dated as of May 20, 2020 Exhibit 10.1 May 20, 2020 Siobhan Nolan Mangini Dear Siobhan, On behalf of NGM Biopharmaceuticals, Inc. ("NGM" or the "Company"), we are pleased that you will be joining the Company as Chief Financial Officer reporting to me. We believe this position represents an extraordinary opportunity, and we look forward to your joining our exceptional team. Below are details of the compensation and benefits
August 12, 2020	EX-99.1	NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results -- Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer -- -- Aldafermin continues to advance toward l Exhibit 99.1 NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results - Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer - - Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies - - In
August 12, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
June 16, 2020	424B5	$150,000,000 NGM Biopharmaceuticals, Inc. Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238991 Prospectus $150,000,000 NGM Biopharmaceuticals, Inc. Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell s
June 12, 2020	CORRESP	- CORRESP NGM BIOPHARMACEUTICALS, INC. 333 Oyster Point Boulevard South San Francisco, California 94080 (650) 243-5555 June 12, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Courtney Lindsay Re: NGM Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 5, 2020 Fi
June 8, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
June 5, 2020	S-3	- S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 5, 2020 Registration No.
June 5, 2020	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associa
June 5, 2020	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.5 Exhibit 4.5 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] org
June 5, 2020	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 NGM BIOPHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF NGM BIOPHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associa
June 5, 2020	EX-4.3	Form of Debt Indenture. EX-4.3 Exhibit 4.3 NGM BIOPHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE DATED AS OF [●], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi
June 5, 2020	EX-1.2	Open Market Sale AgreementSM, dated June 5, 2020, between the registrant and Jefferies LLC. EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM June 5, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’
May 27, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 13, 2020	EX-99.1	NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results -- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) Exhibit 99.1 NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results - Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) - - Continuing enrollment in Phase 2b ALPINE 2/3 clinical study of aldafermin in NASH patients with F2-F3 fibrosis; topline data readout s
May 13, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commissi
May 13, 2020	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
May 8, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
April 8, 2020	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
April 8, 2020	DEFA14A	NGM / NGM BIOPHARMACEUTICALS INC DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
April 2, 2020	SC 13D/A	NGM / NGM BIOPHARMACEUTICALS INC / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name
March 17, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commis
March 17, 2020	EX-99.1	NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights -- Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonst Exhibit 99.1 NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights - Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive effect on all key liver histology and biomarker measures of disease – - Commenced Phase 2b ALPINE 2/3 study of aldafermin
March 17, 2020	EX-21.1	Subsidiaries of NGM Biopharmaceuticals, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Name Jurisdiction of Incorporation or Organization NGM Biopharmaceuticals Australia Pty Ltd. Australia
March 17, 2020	S-8	NGM / NGM BIOPHARMACEUTICALS INC S-8 - - S-8 As filed with the U.S. Securities and Exchange Commission on March 17, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of Incorporation or organization
March 17, 2020	EX-4.3	Description of Capital Stock. Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NGM Biopharmaceuticals, Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following summary of the terms of our common stock is base
March 17, 2020	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38853 NGM BIOPHARMACEUTICALS, I
March 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commiss
February 24, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
February 24, 2020	EX-99.1	NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement Exhibit 99.1 NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo - Clinically meaningful response rates of 38% of patients treated with aldafermin having liver fib
February 13, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
February 11, 2020	SC 13G	NGM / NGM BIOPHARMACEUTICALS INC / Rho Ventures V, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 13, 2020	EX-99.1	This presentation contains forward-looking statements, including, but not limited to, statements regarding potential indications for, and planned development of, product candidates in NGM’s pipeline; the planned timing of initiation, enrollment and r NGM Biopharmaceuticals, Inc. CORPORATE OVERVIEW Novel Biology. Powerful Medicines. Transformative Impact. NASDAQ: NGM Exhibit 99.1 This presentation contains forward-looking statements, including, but not limited to, statements regarding potential indications for, and planned development of, product candidates in NGM’s pipeline; the planned timing of initiation, enrollment and results of NGM’s cli
January 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Comm
December 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (
November 26, 2019	SC 13G	NGM / NGM BIOPHARMACEUTICALS INC / Topspin Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 NGM Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) April 8, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
November 12, 2019	10-Q	NGM / NGM BIOPHARMACEUTICALS INC 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
November 12, 2019	EX-99.1	NGM Reports Business Highlights and Third Quarter 2019 Financial Results - Announced positive interim results from ongoing 24-week Phase 2 study evaluating 1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients Exhibit 99.1 NGM Reports Business Highlights and Third Quarter 2019 Financial Results - Announced positive interim results from ongoing 24-week Phase 2 study evaluating 1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients - - Anticipates full Cohort 4 data, including biopsy assessments in Q1 2020 - - Disclosed complement C3 as the target for NGM621, an inhi
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Com
October 18, 2019	SC 13D/A	NGM / NGM BIOPHARMACEUTICALS INC / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name
October 7, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commi
October 7, 2019	EX-99.1	NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at Exhibit 99.1 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH -Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo - - Statistically significant improvements also observed across key non-invasive biomarkers of metabolism, i
August 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation) (Commi
August 12, 2019	EX-99.1	NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results - Initiated Phase 1 clinical study of NGM621 for the treatment of dry age-related macular degeneration (AMD) - - Completed enrollment of 1 mg cohort of 24-week Phase 2 Exhibit 99.1 NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results - Initiated Phase 1 clinical study of NGM621 for the treatment of dry age-related macular degeneration (AMD) - - Completed enrollment of 1 mg cohort of 24-week Phase 2 study of NGM282 (aldafermin) in NASH patients; Planned data readouts over next 3 – 6 months - - Robust clinical stage pipeline now spans
August 12, 2019	10-Q	NGM / NGM BIOPHARMACEUTICALS INC 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
May 17, 2019	SC 13D/A	NGM / NGM BIOPHARMACEUTICALS INC / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name
May 16, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation)
May 16, 2019	EX-99.1	NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results -Advanced NGM282 into Phase 2b ALPINE 2/3 clinical study in NASH- -Received $177.8 million in aggregate net proceeds in April from Initial Public Offering and private placemen EX-99.1 Exhibit 99.1 NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results -Advanced NGM282 into Phase 2b ALPINE 2/3 clinical study in NASH- -Received $177.8 million in aggregate net proceeds in April from Initial Public Offering and private placement with Merck- South San Francisco, CA, May 16, 2019 – NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology
May 16, 2019	10-Q	NGM / NGM BIOPHARMACEUTICALS INC 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38853 NGM BIOPHARMACEUTICALS, INC.
April 12, 2019	EX-99.E	Power of Attorney EX-99.E EXHIBIT E Power of Attorney The undersigned, a managing partner of The Column Group Management LP, hereby constitutes and appoints each of Gary A. Jungels, Jennifer J. Carlson and Cathy Franczyk, for so long as they are affiliated with a law firm representing The Column Group, LLC, the undersigned’s true and lawful attorney-in-fact, each with the power to act alone for the undersigned and
April 12, 2019	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us. Dated: April 12, 2019 THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Jennifer J. Carlson, Attorney-in-Fact By: /s/ Jennifer J. Carlson, Attorney-in-Fact THE COLUMN GROUP II, LP THE COLUMN GROUP II GP, LP By: Th
April 12, 2019	SC 13D	NGM / NGM BIOPHARMACEUTICALS INC / COLUMN GROUP L P - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NGM BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62921N 105 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name, A
April 9, 2019	SC 13G	NGM / NGM BIOPHARMACEUTICALS INC / Merck & Co., Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NGM Biopharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62921N 10 5 (CUSIP Number) April 8, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
April 8, 2019	EX-3.1	Amended and Restated Certificate of Incorporation EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NGM BIOPHARMACEUTICALS, INC. David J. Woodhouse hereby certifies that: ONE: The original name of this corporation is NGM Biopharmaceuticals, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was December 20, 2007. TWO: He is the duly e
April 8, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2019 NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or Other Jurisdiction of Incorporation)
April 4, 2019	S-8	NGM / NGM BIOPHARMACEUTICALS INC S-8 S-8 As filed with the U.S. Securities and Exchange Commission on April 4, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NGM BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1679911 (State or other jurisdiction of Incorporation or organizat

NGM / NGM Biopharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)